Bone Biologics Corp. is a developer of orthobiologic products for spine fusion markets. Bone Biologics Corp. is based in BURLINGTON, Mass.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-3.11M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.21 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -57.07% |
| Return on Assets (Trailing 12 Months) | -52.54% |
| Current Ratio (Most Recent Fiscal Quarter) | 13.37 |
| Quick Ratio (Most Recent Fiscal Quarter) | 13.37 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $1.76 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.17 |
| Earnings per Share (Most Recent Fiscal Year) | $-2.65 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.17 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Medical Devices |
| Common Shares Outstanding | 3.39M |
| Free Float | 3.22M |
| Market Capitalization | $1.26M |
| Average Volume (Last 20 Days) | 0.04M |
| Beta (Past 60 Months) | 0.91 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 5.00% |
| Percentage Held By Institutions (Latest 13F Reports) | 34.30% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |